Similarly, the ATTACH (Anti-TNF-α in Congestive Heart Failure) trial investigating infliximab, a chimeric monoclonal TNF-α antibody, in NYHA III-IV patients highlighted concerns about the safety of TNF-α antagonism in advanced HF. Here, TNF is linked to hydrops fetalis.